If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing…
Enters into Agreement with Bradley L. Radoff and Michael TorokBOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:…
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused…
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a…
SEOUL, South Korea, April 16, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, a global leader in the development of therapies for patients with…
Clario's Advanced AI-Powered Platform Streamlines Clinical Document Processing to Facilitate Faster Drug Development Timelines PHILADELPHIA, April 16, 2025 /PRNewswire/ --…
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 16, 2025 /PRNewswire/ -- Equity Insider News…
PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced…
LAS VEGAS, April 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its partner, Ainnova…
Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…